Markets:

Overview

News

Currencies

International

Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

74.89 -3.48 (-4.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 11, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

October 28, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

From Spruce Biosciences, Inc.

Via Business Wire

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 12, 2024

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 12, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA

July 11, 2024

Via AB Newswire

Spruce Biosciences Recognized as a Bay Area Best Place to Work

June 06, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder ↗

June 04, 2024

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

Via Benzinga

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

June 04, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

June 03, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

May 23, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

May 22, 2024

From Spruce Biosciences, Inc.

Via Business Wire

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗

May 13, 2024

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 13, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in May Investor Conferences

May 01, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Pfizer Q1 Earnings and Revenues Beat Estimates ↗

May 01, 2024

PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.

Via Talk Markets

Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

April 30, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

April 22, 2024

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 21, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall ↗

March 14, 2024

Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compliance. Analysts downgrade ratings and adjust price targets amid...

Via Benzinga

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 14, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views ↗

March 14, 2024

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28....

Via Benzinga

Topics Stocks

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 14, 2024

Via Benzinga

Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings ↗

March 14, 2024

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The...

Via Benzinga

Topics Stocks

US Stocks Higher; Producer Prices Rise 0.6% In February ↗

March 14, 2024

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P...

Via Benzinga

Topics Stocks

Is Altria Giving Up on Anheuser-Busch (BUD) Stock? ↗

March 14, 2024

Anheuser-Busch stock is falling on Thursday following news that 10% holder Altria is selling a portion of its stake in BUD shares.

Via InvestorPlace

Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday? ↗

March 14, 2024

Spruce Biosciences' latest CAH studies: CAHmelia-203 & CAHptain-205. Discover insights on tildacerfont's efficacy, safety, and pharmacokinetics in adult & pediatric CAH patients.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 14, 2024

Via Benzinga

Why Is Fisker (FSR) Stock Down 41% Today? ↗

March 14, 2024

Fisker stock is falling hard on Thursday as FSR investors react to reports that the EV company is preparing to file for bankruptcy.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.